Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Not Confirmed
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Not Confirmed
Not Confirmed
29-31 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
KY/TN Water Profession...KY/TN Water Professionals
Industry Trade Show
Not Confirmed
27-30 July, 2025
Chemicals AmericaChemicals America
Industry Trade Show
Not Confirmed
29-31 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
27 Feb 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/02/27/3033883/36946/en/Orbus-Therapeutics-Appoints-Jason-Levin-Co-founder-and-COO-to-President.html
22 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/11/22/2986091/36946/en/Combination-of-Eflornithine-and-Lomustine-Demonstrates-Clinically-Meaningful-Improvements-in-Overall-Survival-OS-and-Progression-Free-Survival-PFS-in-Patients-with-Recurrent-Astroc.html
06 Sep 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/09/06/2738464/36946/en/Orbus-Therapeutics-Announces-First-Patient-Enrolled-in-Phase-1-Clinical-Study-in-Newly-Diagnosed-Glioblastoma.html
10 Jan 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/01/10/2586093/36946/en/Orbus-Therapeutics-Enters-Exclusive-License-Agreement-for-Intellectual-Property-Related-to-Treatment-of-Rare-Pediatric-Syndrome-with-Eflornithine.html
19 Jan 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/01/19/2369409/36946/en/Orbus-Therapeutics-Phase-3-Eflornithine-STELLAR-Study-Reaches-Full-Patient-Enrollment.html
28 Sep 2021
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2021/09/28/2304662/36946/en/Orbus-Therapeutics-Granted-European-Patent-for-Method-of-Use-for-Eflornithine.html
Details:
A combination of an ODC inhibitor, eflornithine and cancer DNA inhibitor lomustine is being investigated in patients with grade 3 IDH mutant astrocytoma.
Lead Product(s): Eflornithine Hydrochloride,Lomustine
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 22, 2024
Lead Product(s) : Eflornithine Hydrochloride,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eflornithine & Lomustine Combination Shows Survival Benefit in Astrocytoma IDH Mutant
Details : A combination of an ODC inhibitor, eflornithine and cancer DNA inhibitor lomustine is being investigated in patients with grade 3 IDH mutant astrocytoma.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2024
Details:
DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
Lead Product(s): Eflornithine Hydrochloride
Therapeutic Area: Rare Diseases and Disorders Brand Name: DFMO
Study Phase: UndisclosedProduct Type: Other Small Molecule
Sponsor: Michigan State University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 01, 2023
Lead Product(s) : Eflornithine Hydrochloride
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Michigan State University
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 01, 2023
Details:
DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, which is investigated in combination with eflornithine in patients newly diagnosed with glioblastoma.
Lead Product(s): Eflornithine Hydrochloride,Temozolomide
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 09, 2023
Lead Product(s) : Eflornithine Hydrochloride,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DFMO (eflornithine) is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, which is investigated in combination with eflornithine in patients newly diagnosed with glioblastoma.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 09, 2023
Details:
Enrollment of patients in Phase 3 STELLAR trial for DFMO (eflornithine hydrochloride), a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase in patients in patients with recurrent anaplastic astrocytoma.
Lead Product(s): Eflornithine Hydrochloride,Lomustine
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 19, 2022
Lead Product(s) : Eflornithine Hydrochloride,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orbus Therapeutics’ Phase 3 Eflornithine STELLAR Study Reaches Full Patient Enrollment
Details : Enrollment of patients in Phase 3 STELLAR trial for DFMO (eflornithine hydrochloride), a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase in patients in patients with recurrent anaplastic astrocytoma.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2022
Details:
Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
Lead Product(s): Eflornithine Hydrochloride,Lomustine
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 28, 2021
Lead Product(s) : Eflornithine Hydrochloride,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orbus Therapeutics Granted European Patent for Method of Use for Eflornithine
Details : Eflornithine is a novel cytostatic agent that irreversibly inhibits ornithine decarboxylase, a key enzyme in mammalian polyamine biosynthesis that is up-regulated in certain types of cancer.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2021
Details:
Patent relates to a solution of eflornithine for oral administration currently being evaluated in Orbus’ Phase 3 STELLAR study in rare brain cancer.
Lead Product(s): Eflornithine Hydrochloride,Lomustine
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 23, 2020
Lead Product(s) : Eflornithine Hydrochloride,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Orbus Therapeutics Receives U.S. Patent for Eflornithine Formulations
Details : Patent relates to a solution of eflornithine for oral administration currently being evaluated in Orbus’ Phase 3 STELLAR study in rare brain cancer.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 23, 2020
Details:
The expanded Series A funding will support the ongoing STELLAR study, a Phase 3 clinical trial studying eflornithine in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant chemotherapy.
Lead Product(s): Eflornithine Hydrochloride,Lomustine
Therapeutic Area: Oncology Brand Name: DFMO
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Longitude Capital
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 22, 2020
Lead Product(s) : Eflornithine Hydrochloride,Lomustine
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Longitude Capital
Deal Size : $71.0 million
Deal Type : Series A Financing
Details : The expanded Series A funding will support the ongoing STELLAR study, a Phase 3 clinical trial studying eflornithine in patients with anaplastic astrocytoma whose cancer has recurred following radiation and adjuvant chemotherapy.
Product Name : DFMO
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 22, 2020
ABOUT THIS PAGE